Fact check · Version 1 · Sources checked
“The advisory vote added Semax to the 503A list or approved it.”
The Peptide Field explains research. Its pages are not independently medically reviewed, and they do not diagnose, prescribe, or recommend treatment.
Misleading
This statement leaves out a limit that changes its meaning.
RAPS reported an 8-5 advisory-committee vote in favor of adding Semax to the 503A list. FDA says advisory recommendations are non-binding, and the briefing says FDA had not made its final determination. No final FDA rule or listing was identified in this review.
- What this answer is based on
- This answer uses an official regulator record or a specific product label.
- Limits of this answer
- The July 2026 advisory vote and U.S. 503A status as reviewed August 30, 2026; a recommendation is not a final FDA decision or drug approval. These limits show which substance, product, people, use, place, and time the answer covers. A different product or situation can have a different answer.
- Topic
- Whether a specific product has an approval or another official status.
Sources for this fact check
Show 5 sources
01FDA advisory committee backs two more peptides, rejects one for compounding listRegulatory Affairs Professionals Society · Reference · 202602July 23-24, 2026 Pharmacy Compounding Advisory Committee meetingU.S. Food and Drug Administration · Regulatory · 202603FDA evaluation of Semax-related bulk drug substancesU.S. Food and Drug Administration · FDA review · 202604Bulk drug substances used in compounding under section 503AU.S. Food and Drug Administration · Regulatory · 20260521 CFR 216.23 bulk drug substances listElectronic Code of Federal Regulations · Regulatory · 2026
- Sources checked by
- Site editor · Editorial review